Design and rationale of TROCADERO: A TRial of Caffeine to Alleviate DyspnEa Related to ticagrelOr

American Heart Journal

Volumn 170, Issue 3, 2015, Pages 465-470

  Lindholm, Daniel ^a,b   Storey, Robert F ^c   Christersson, Christina ^a   Halvorsen, Sigrun ^d   Grove, Erik L ^e   Braun, Oscar Ö ^f   Varenhorst, Christoph ^a,b   James, Stefan K ^a,b  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA CLINICAL RESEARCH CENTER   (Sweden)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

^d ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^e AARHUS UNIVERSITY HOSPITAL   (Denmark)

^f LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CAFFEINE; PLACEBO; TICAGRELOR; ADENOSINE; ADENOSINE RECEPTOR BLOCKING AGENT; PURINERGIC P2Y RECEPTOR ANTAGONIST;

ACUTE CORONARY SYNDROME; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PARALLEL DESIGN; PHASE 2 CLINICAL TRIAL; PLATELET REACTIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT RESPONSE; VISUAL ANALOG SCALE; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; CLINICAL TRIAL; DOSE RESPONSE; ELECTROCARDIOGRAPHY; PATHOPHYSIOLOGY;

ACUTE CORONARY SYNDROME; ADENOSINE; CAFFEINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DYSPNEA; ELECTROCARDIOGRAPHY; PURINERGIC P1 RECEPTOR ANTAGONISTS; PURINERGIC P2Y RECEPTOR ANTAGONISTS;

EID: 84941730915     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2015.06.014     Document Type: Article

References (46)

1. L. Wallentin, R.C. Becker, A. Budaj, and et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes N Engl J Med 361 11 2009 1045 1057
2. P. Kolh, S. Windecker, F. Alfonso, and et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) Eur Heart J 2014 Oxford University Press ehu278
3. P.T. O'Gara, F.G. Kushner, D.D. Ascheim, and et al. 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction J Am Coll Cardiol 61 4 2013 e78 e140
4. E.A. Amsterdam, N.K. Wenger, R.G. Brindis, and et al. 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Circulation 130(25) 2014 Lippincott Williams & Wilkins e344 e426
5. SWEDEHEART working group SWEDEHEART Annual report 2013 2014 1 138
6. R.F. Storey, K.P. Bliden, S.B. Patil, and et al. Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET/OFFSET study J Am Coll Cardiol 56 3 2010 185 193
7. R.F. Storey, R.C. Becker, R. Harrington, and et al. Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes Eur Heart J 32 23 2011 2945 2953
8. S. Husted, H. Emanuelsson, S. Heptinstall, and et al. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin Eur Heart J 27 9 2006 1038 1047
9. C.P. Cannon, S. Husted, R. Harrington, and et al. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial J Am Coll Cardiol 50 19 2007 1844 1851
10. M. Gaubert, M. Laine, T. Richard, and et al. Effect of ticagrelor-related dyspnea on compliance with therapy in acute coronary syndrome patients Int J Cardiol 173 1 2014 120 121
11. D.L. Bhatt, A.M. Lincoff, C.M. Gibson, and et al. Intravenous platelet blockade with cangrelor during PCI N Engl J Med 361 24 2009 2330 2341
12. R. Harrington, G.W. Stone, S. McNulty, and et al. Platelet inhibition with cangrelor in patients undergoing PCI N Engl J Med 361 24 2009 2318 2329
13. D.L. Bhatt, G.W. Stone, K.W. Mahaffey, and et al. Effect of platelet inhibition with cangrelor during PCI on ischemic events N Engl J Med 368 14 2013 1303 1313 [130310091208003]
14. R.C. Welsh, S.V. Rao, U. Zeymer, and et al. A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-PCI trial Circ Cardiovasc Interv 5 3 2012 336 346
15. S. Nylander, E.A. Femia, M. Scavone, and et al. Ticagrelor inhibits human platelet aggregation via adenosine in addition to P2Y12 antagonism J Thromb Haemost 11 10 2013 1867 1876
16. M. Cattaneo, R. Schulz, and S. Nylander Adenosine-mediated effects of ticagrelor: evidence and potential clinical relevance J Am Coll Cardiol 63 23 2014 2503 2509
17. D. Armstrong, C. Summers, L. Ewart, and et al. Characterization of the adenosine pharmacology of ticagrelor reveals therapeutically relevant inhibition of equilibrative nucleoside transporter 1 J Cardiovasc Pharmacol Ther 2014 SAGE Publications [1074248413511693]
18. J. Ohman, R. Kudira, S. Albinsson, and et al. Ticagrelor induces adenosine triphosphate release from human red blood cells Biochem Biophys Res Commun 418 4 2012 754 758
19. L. Bonello, M. Laine, N. Kipson, and et al. Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome J Am Coll Cardiol 63 9 2014 872 877
20. A. Wittfeldt, H. Emanuelsson, G. Brandrup-Wognsen, and et al. Ticagrelor enhances adenosine-induced coronary vasodilatory responses in humans J Am Coll Cardiol 61 7 2013 723 727
21. P. Smits, P. Boekema, R. De Abreu, and et al. Evidence for an antagonism between caffeine and adenosine in the human cardiovascular system J Cardiovasc Pharmacol 10 2 1987 136 143
22. P. Smits, J.W. Lenders, and T. Thien Caffeine and theophylline attenuate adenosine-induced vasodilation in humans Clin Pharmacol Ther 48 4 1990 410 418
23. K. Varani, F. Portaluppi, S. Merighi, and et al. Caffeine alters A2A adenosine receptors and their function in human platelets Circulation 99 19 1999 2499 2502
24. K. Varani, F. Portaluppi, S. Gessi, and et al. Dose and time effects of caffeine intake on human platelet adenosine A(2A) receptors: functional and biochemical aspects Circulation 102 3 2000 285 289
25. E.I. Lev, M.E. Arikan, M. Vaduganathan, and et al. Effect of caffeine on platelet inhibition by clopidogrel in healthy subjects and patients with coronary artery disease Am Heart J 154 4 2007 694.e1 694.e7
26. M. Noordzij, C.S.P.M. Uiterwaal, L.R. Arends, and et al. Blood pressure response to chronic intake of coffee and caffeine: a meta-analysis of randomized controlled trials J Hypertens 23 5 2005 921 928
27. D.E. Grobbee, E.B. Rimm, E. Giovannucci, and et al. Coffee, caffeine, and cardiovascular disease in men N Engl J Med 323 15 1990 1026 1032
28. S.C. Larsson, S. Männistö, M.J. Virtanen, and et al. Coffee and tea consumption and risk of stroke subtypes in male smokers Stroke 39 6 2008 1681 1687
29. S.C. Larsson, J. Virtamo, and A. Wolk Coffee consumption and risk of stroke in women Stroke 42 4 2011 908 912
30. E. Lopez-Garcia, F. Rodriguez-Artalejo, K.M. Rexrode, and et al. Coffee consumption and risk of stroke in women Circulation 119 8 2009 1116 1123
31. N. Iwai, H. Ohshiro, Y. Kurozawa, and et al. Relationship between coffee and green tea consumption and all-cause mortality in a cohort of a rural Japanese population J Epidemiol 12 3 2002 191 198
32. P. Kleemola, P. Jousilahti, P. Pietinen, and et al. Coffee consumption and the risk of coronary heart disease and death Arch Intern Med 160 22 2000 3393 3400
33. E. Lopez-Garcia, R.M. van Dam, W.C. Willett, and et al. Coffee consumption and coronary heart disease in men and women: a prospective cohort study Circulation 113 17 2006 2045 2053
34. I. Stensvold, A. Tverdal, and B.K. Jacobsen Cohort study of coffee intake and death from coronary heart disease over 12 years BMJ 312 7030 1996 544 545
35. M.C. Cornelis, A. El-Sohemy, E.K. Kabagambe, and et al. Coffee, CYP1A2 genotype, and risk of myocardial infarction JAMA 295 10 2006 1135 1141
36. J.J. de Vreede-Swagemakers, A.P. Gorgels, M.P. Weijenberg, and et al. Risk indicators for out-of-hospital cardiac arrest in patients with coronary artery disease J Clin Epidemiol 52 7 1999 601 607
37. L.B. Chelsky, J.E. Cutler, K. Griffith, and et al. Caffeine and ventricular arrhythmias. An electrophysiological approach JAMA 264 17 1990 2236 2240
38. T.B. Graboys, C.M. Blatt, and B. Lown The effect of caffeine on ventricular ectopic activity in patients with malignant ventricular arrhythmia Arch Intern Med 149 3 1989 637 639
39. M.G. Myers Caffeine and cardiac arrhythmias Ann Intern Med 114 2 1991 147 150
40. N.D. Freedman, Y. Park, C.C. Abnet, and et al. Association of coffee drinking with total and cause-specific mortality N Engl J Med 366 20 2012 1891 1904
41. J.J.V. McMurray, J.R. Teerlink, G. Cotter, and et al. Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials JAMA 298 17 2007 2009 2019
42. G.M. Felker, K.L. Lee, D.A. Bull, and et al. Diuretic strategies in patients with acute decompensated heart failure N Engl J Med 364 9 2011 797 805
43. M.J. Price, P.B. Berger, P.S. Teirstein, and et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial JAMA 305 11 2011 1097 1105
44. J.-P. Collet, T. Cuisset, G. Rangé, and et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting N Engl J Med 367 22 2012 2100 2109
45. U.S. Tantry, L. Bonello, D. Aradi, and et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding 2013 2261 2273
46. D.S. Ander, I.P. Aisiku, J.J. Ratcliff, and et al. Measuring the dyspnea of decompensated heart failure with a visual analog scale: how much improvement is meaningful? Congest Heart Fail 10 4 2004 188 191